Mode
Text Size
Log in / Sign up
N/A N=154

ProMRI Study of the Iforia ICD System (Phase C)

Implantable Cardioverter-Defibrillator With Magnetic Resonance Imaging

Enrolled (actual)
154
Serious AEs
14.9%
Results posted
Oct 2015
Primary outcome: Primary: MRI and ICD System Related Serious Adverse Device Effect (SADE) Free Rate — 100 percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Patients with a ProMRI ICD System (Device); Magnetic Resonance Imaging (MRI) scan (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Biotronik, Inc.
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
MRI and ICD System Related Serious Adverse Device Effect (SADE) Free Rate
100
PRIMARY
Percentage of Participants Free of Ventricular Pacing Threshold Rise
100
PRIMARY
Percentage of Participants Free of R-wave Sensing Attenuation
99.3

Summary

The objective of the ProMRI Study is to demonstrate the clinical safety of the ProMRI ICD System when used under specific MRI conditions.

Eligibility Criteria

Inclusion Criteria

The following initial inclusion criteria must be met for a subject to be enrolled and considered for the MRI-procedure:

  • Age greater than or equal to 18 years
  • Able and willing to complete MRI testing
  • Able to provide written informed consent
  • Available for follow-up visit at the study site
  • Implanted with an ICD System consisting only of an Iforia DR-T and Linoxsmart S 65 / Linoxsmart SD 65/18 with Setrox S 53 atrial lead or Iforia VR-T DX and Linoxsmart S DX 65/15 or Linoxsmart S DX 65/17.
  • ICD implanted pectorally
  • All ICD system components implanted, repositioned, or exchanged at least 5 weeks prior to enrollment
  • Underlying rhythm identifiable during sensing test
  • All pacing thresholds are measureable and are less than or equal to 2.0 V @ 0.4 ms (Criterion does not apply to atrial pacing threshold for subjects with an Iforia DR-T that have AF and are permanently programmed to VVI and for subjects with an Iforia VR-T DX)
  • Ventricular sensing is measurable and >6.5mV
  • Absence of phrenic nerve stimulation at 5.0V and 1.0 ms
  • Pacing impedance is between 200 and 1500 ohm
  • Shock Impedance is between 30 and 90 ohm
  • Able and willing to use the CardioMessenger II

At the pre-MRI procedure, the following procedure-related criteria must be met for the subject to undergo the MRI scan:

  • Absence of phrenic nerve stimulation at 5.0V @ 1.0 ms
  • |pacing threshold at Pre-MRI follow-up - pacing threshold at baseline| ≤ 0.5 V (ICD Lead Only)
  • All pacing thresholds are measureable and are less than or equal to 2.0 V @ 0.4 ms (Criterion does not apply to atrial pacing threshold for subjects with an Iforia DR-T that have AF and are permanently programmed to VVI and for subjects with an Iforia VR-T DX.)
  • Ventricular sensing is measurable and >6.5mV
  • The ICD system has been implanted for at least six weeks.
  • Subject did not have an ICD or lead explant, exchange or reposition in the previous 6 weeks.
  • All lead pacing impedances are between 200 and 1500 ohm
  • Shock impedance is between 30 and 90 ohm
  • Battery status is at least 30% of capacity
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02096692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search